{"id":"sofetabart-mipitecan","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting thymidylate synthase, Sofetabart Mipitecan disrupts DNA synthesis and repair, leading to cell death in rapidly dividing cancer cells. This mechanism is particularly effective in tumors with high levels of thymidylate synthase expression.","oneSentence":"Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:17.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06400472","phase":"PHASE1","title":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-20","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":495}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY4170156"],"phase":"phase_3","status":"active","brandName":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}